Nancy Haigwood
#23,842
Most Influential Person Now
American scientist
Nancy Haigwood's AcademicInfluence.com Rankings
Nancy Haigwoodbiology Degrees
Biology
#1292
World Rank
#2192
Historical Rank
#657
USA Rank
Microbiology
#71
World Rank
#91
Historical Rank
#31
USA Rank
Virology
#383
World Rank
#391
Historical Rank
#57
USA Rank
Immunology
#1020
World Rank
#1046
Historical Rank
#108
USA Rank
Download Badge
Biology
Nancy Haigwood's Degrees
- PhD Microbiology Oregon Health & Science University
Why Is Nancy Haigwood Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nancy Logan Haigwood is an American scientist. She is a professor and the director of the Oregon National Primate Research Center. Haigwood is an HIV/AIDS researcher and serves as a volunteer board member on the Cascade AIDS Project. She is an advocate of science education and outreach.
Nancy Haigwood's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis (1992) (705)
- Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys (1999) (594)
- Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. (2004) (468)
- Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. (1991) (307)
- Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines (2005) (255)
- Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival (1997) (237)
- Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. (1991) (237)
- Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies (2002) (173)
- Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma (1999) (169)
- Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. (1996) (158)
- Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques (2016) (153)
- Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development (2003) (139)
- Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons (1992) (139)
- Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques (2010) (139)
- DNA vaccine strategies: candidates for immune modulation and immunization regimens. (2003) (128)
- Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers (2008) (127)
- DNA sequence organization of the β-globin complex in the BALB/c mouse (1980) (125)
- Use of broadly neutralizing antibodies for HIV‐1 prevention (2017) (124)
- Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope (2005) (117)
- Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies (2004) (108)
- The Use of Nonhuman Primate Models in HIV Vaccine Development (2008) (108)
- Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. (1995) (107)
- Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of Neutralizing Antibodies (2011) (103)
- Human natural killer cells mediate adaptive immunity to viral antigens (2019) (102)
- High Maternal HIV-1 Viral Load During Pregnancy Is Associated With Reduced Placental Transfer of Measles IgG Antibody (2005) (98)
- High Specific Infectivity of Plasma Virus from the Pre-Ramp-Up and Ramp-Up Stages of Acute Simian Immunodeficiency Virus Infection (2009) (97)
- Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge (2003) (97)
- Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. (1990) (94)
- Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. (1991) (90)
- N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. (1991) (85)
- Vaccine Delivery to the Oral Cavity Using Coated Microneedles Induces Systemic and Mucosal Immunity (2014) (82)
- The functional domains of coagulation factor VIII:C. (1986) (80)
- Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection (1993) (78)
- Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge1 (2006) (77)
- HIV-1 envelope gp120 alters astrocytes in human brain cultures. (1993) (74)
- Origins of HIV and the AIDS Pandemic (2011) (73)
- Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. (1994) (71)
- B‐Cell Abnormalities in AIDS: Stable and Clonally‐Restricted Antibody Response in HIV‐1 Infection (1993) (70)
- Predictive value of primate models for AIDS. (2004) (70)
- Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques (2006) (70)
- Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. (2004) (69)
- The Critical Role of Nonhuman Primates in Medical Research (2017) (66)
- Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. (1992) (65)
- V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. (1993) (63)
- Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. (1997) (63)
- Protection from pathogenic SIV challenge using multigenic DNA vaccines. (1999) (62)
- Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. (2012) (61)
- Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV‐1SF2 (1995) (55)
- A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. (2019) (55)
- Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1 (2014) (54)
- Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques (2017) (54)
- Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies (2007) (51)
- Animal models in HIV-1 protection and therapy (2015) (50)
- Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens (2016) (49)
- SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans (2013) (48)
- Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and Revaccination (2009) (46)
- Humoral immunity to HIV, SIV, and SHIV. (1998) (45)
- Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. (1992) (43)
- Neutralizing Polyclonal IgG Present during Acute Infection Prevents Rapid Disease Onset in Simian-Human Immunodeficiency Virus SHIVSF162P3-Infected Infant Rhesus Macaques (2013) (42)
- Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells (2012) (40)
- Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA (2014) (40)
- Update on animal models for HIV research (2009) (39)
- Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. (1990) (35)
- Transmission of HIV-1 in the face of neutralizing antibodies. (2007) (34)
- Improvement of antibody responses by HIV envelope DNA and protein co-immunization. (2014) (34)
- Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits (2014) (34)
- Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges (2018) (34)
- Passive and active antibody studies in primates to inform HIV vaccines (2018) (32)
- ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics (2020) (32)
- Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. (1991) (31)
- Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity (2020) (30)
- Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3 (2006) (30)
- HIV molecular organization, pathogenicity and treatment. (1993) (29)
- The Infectious Molecular Clone and Pseudotyped Virus Models of Human Immunodeficiency Virus Type 1 Exhibit Significant Differences in Virion Composition with Only Moderate Differences in Infectivity and Inhibition Sensitivity (2009) (29)
- Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses (2007) (28)
- Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. (2019) (28)
- Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. (1992) (28)
- Neutralizing Antibodies and Control of HIV: Moves and Countermoves (2012) (26)
- HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. (2010) (26)
- Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. (2016) (26)
- Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials (2018) (25)
- Locations of three repetitive sequence families found in BALB/c adult beta-globin clones. (1981) (25)
- Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. (1994) (25)
- Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. (2004) (24)
- Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm) (1999) (24)
- Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. (2012) (23)
- New recombinant vaccines based on the use of prokaryotic antigen-display systems (2004) (23)
- Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology (2019) (22)
- Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees. (1996) (22)
- Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge (2017) (21)
- Immunization against SIVmne in macaques using multigenic DNA vaccines (1999) (21)
- AIDS Vaccine Development (1998) (20)
- Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. (1992) (19)
- Perinatal transmission of SHIV‐SF162P3 in Macaca nemestrina (2004) (18)
- Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N- and C-termini. (1989) (18)
- Multigene DNA prime‐boost vaccines for SHIV89.6P (2003) (18)
- Macaque blood‐derived antigen‐presenting cells elicit SIV‐specific immune responses (2000) (17)
- Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals (1993) (17)
- Animal models for perinatal transmission of HIV-1. (2006) (17)
- Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic (2021) (16)
- Role of neutralizing antibodies in HIV infection. (2003) (16)
- Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. (2016) (15)
- DNA sequence organization of the beta-globin complex in the BALB/c mouse. (1980) (15)
- Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. (1992) (15)
- Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. (2017) (14)
- The recognition site of type II restriction enzyme BglI is interrupted. (1980) (13)
- DNA fragments of the Mus musculus beta globin haplotypes Hbbs and Hbbd. (1979) (13)
- Progress and challenges in therapies for AIDS in nonhuman primate models (1999) (11)
- Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques (2019) (11)
- Anti-idiotypic antisera raised against monoclonal antibody specific for a p24 gag region epitope detects a common interspecies idiotype associated with anti-HIV responses. (1990) (11)
- Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission (2021) (10)
- Commissioned Paper: Comparison of Immunity to Pathogens in Humans, Chimpanzees, and Macaques (2011) (9)
- Importance of conformation on the neutralizing antibody response to HIV-1 gp120. (1991) (9)
- IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. (2019) (9)
- An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques (2020) (9)
- Delivery strategies for novel vaccine formulations. (2012) (8)
- Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis (2022) (8)
- Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure (2020) (8)
- Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development (2020) (8)
- Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth (2018) (8)
- Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines. (2020) (8)
- E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells (2016) (7)
- Differentiation of a passive vaccine and the humoral immune response toward infection: analysis of phage displayed peptides. (2006) (7)
- AIDS Vaccine 2005. (2005) (7)
- AminoTrack: Automating the Entry and Analysis of Mutations in Multiple Protein Sequences Using a Spreadsheet Format (2006) (7)
- HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans (2013) (7)
- Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity (2005) (7)
- Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies. (2015) (7)
- Immunization of primates with native, recombinant HIV-SF2 gp120 generates broadly effective neutralizing antibodies directed to conformational epitopes. (1992) (6)
- Blocking and tackling HIV (2009) (6)
- Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding (2021) (5)
- Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge (2021) (5)
- Polyfunctional Tier 2–Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor (2021) (5)
- Antibodies Tip the Balance Towards an HIV Cure. (2019) (5)
- Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine–Induced Anti-V2 Antibodies Alone (2021) (4)
- Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques (2021) (4)
- 280 Mutants of human tissue-plasminogen activator with improved properties in vitro (1988) (3)
- Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques (2021) (3)
- IMPROVEMENT OF T-PA PROPERTIES BY MEANS OF SITE DIRECTED MUTAGENESIS (1987) (3)
- Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques (2017) (2)
- V 3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1 (2005) (2)
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines (2021) (2)
- SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans (2013) (1)
- Antibodies pose a double threat to HIV (2018) (1)
- Insights into neutralizing antibodies and HIV Envelope (2006) (1)
- Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope. (1991) (1)
- Vaccine Delivery to the Oral Cavity Using Coated Microneedles Induces Systemic and Mucosal Immunity (2014) (1)
- HIV: Tied down by its own receptor (2015) (1)
- Nonhuman Primate Models for AIDS (2008) (0)
- HIV vaccine mimicking the RV144 regimen tightly controls and ablates SHIV BaL.P4 infection in rhesus macaques (2018) (0)
- Nucleic acid coding for new peptide plasminogen activator (1994) (0)
- Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials (2018) (0)
- An Aids-free World (2013) (0)
- Tribute to Bonnie Mathieson. (2018) (0)
- Nonhuman primate models for pediatric AIDS (2009) (0)
- High Specific Infectivity of Plasma Virus from the Pre-Ramp-Up and Ramp-Up Stages of Acute Simian Immunodeficiency Virus Infection (cid:1) (2009) (0)
- V1V2 multivalent scaffolds induce focused antibody responses with functional activity, prolonged durability, and modest neutralization potency (2017) (0)
- Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies (2015) (0)
- REPORTE CORTO/SHORT REPORT - PASSIVE IMMUNE GLOBULIN THERAPY AND ITS POTENTIAL FOR REDUCING VIRAL BURDEN (1995) (0)
- non-V3-specific neutralizing antibodies that interfere with gpl20/CD4 binding in human immunodeficiency virus 1-infected humans (0)
- Characterization Of Group-specific Antibodies Generated By Lentivirus Infection Or Subunit Immunization In Primates (1993) (0)
- Cloning and functional testing of rhesus macaque (Macaca mulatta) IL‐9 and IL‐33 (2020) (0)
- Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates (2023) (0)
- Genetic Engineering (1991) (0)
- Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques (2021) (0)
- Post-exposure treatment with neutralizing monoclonal antibodies prevents SHIV infection in infant rhesus macaques and limits establishment of latent viral reservoirs (VAC11P.1102) (2015) (0)
- Too close for comfort. Nancy Haigwood is interviewed by Rex Dalton. (2008) (0)
- gpl20 Generates Broad-Spectrum Neutralizing Antibodies in Baboons (2003) (0)
- AIDS vaccine 2005. 6-9 September 2005, Montreal, Canada (2005) (0)
- A 11 Patent Number : 45 Date of Patent : 5 , 688 , 688 Nov . 18 , 1997 (2017) (0)
- Genetic Engineering (1999) (0)
- Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis (2022) (0)
- A polypeptide having tissue plasminogen activator activity (1986) (0)
- Animal studies and HIV research. Author's reply (2002) (0)
- IL-33 enhances the induction, durability, and breadth of the antibody response to a DNA/protein-based HIV Env vaccine (2017) (0)
- Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge (2004) (0)
- New plasminogen activator (1996) (0)
- Antibodies pose a double threat to HIV (2018) (0)
- Targeting tonsillar B cells with IL-9 and IL-33 enhances the rhesus macaque humoral response to DNA/protein-based HIV envelope vaccine (2022) (0)
- U.S.-Japan Cooperative Medical Science Program. 10th International Conference on Emerging Infectious Diseases in the Pacific Rim. (2007) (0)
- Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity (2020) (0)
- Cell containing nucleic acid coding for plasminogen activator of new peptide (1994) (0)
- CD4+ T cells are dispensable for induction of heterologous tier 2 HIV neutralizing antibodies in rhesus macaques (2020) (0)
- CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques (2021) (0)
- Pediatric AIDS: Maternal-Fetal and Maternal-Infant Transmission of Lentiviruses and Effects on Infant Development in Nonhuman Primates (2008) (0)
- Early prophylaxis impact for newborns at risk for HIV-1 transmission at birth: viral clearance and attenuation with neutralizing monoclonal antibodies in infant rhesus macaques (2016) (0)
- Animal studies and HIV research [5] (multiple letters) (2002) (0)
- Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques (2017) (0)
- Neutralizing Antibodies in Rabbits HIV-Infected Subjects Stimulate Multiclade Neutralization Breadth Developed in Two Envelope Variants Circulating as Initial (2014) (0)
- E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells (2016) (0)
- World Journal of Virology Delivery strategies for novel vaccine formulations (2012) (0)
- Process for producing new peptides plasminogen activators. (1986) (0)
- DNA fragments of the Mus musculus A globin haplotypes Hbbs and Hbbd ( RPC-5 chromatography / restriction enzyme analysis / mouse 13 globin genes / embryonic globin genes ) (0)
- A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque. (2021) (0)
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines (2022) (0)
- Challenge mac251 against Oral SIV Protection of Neonatal Rhesus Macaques Cellular Cytotoxicity-Mediating IgG in Nonneutralizing Antibody-Dependent Evaluation of Passively Transferred, (2006) (0)
- Host factors involved in the viral replication and particle formation could give a new insight into the innate immunity and may turn out to be a good target for therapeutic intervention. Introduction. (2010) (0)
- Characterization of heterologous HIV-1 Tier 2 neutralizing mAbs cloned from a macaque immunized with viral quasispecies present in a human subject with neutralization breadth (2019) (0)
This paper list is powered by the following services:
Other Resources About Nancy Haigwood
What Schools Are Affiliated With Nancy Haigwood?
Nancy Haigwood is affiliated with the following schools:
